Opus Genetics (IRD) Non-Current Debt (2025 - 2026)

Name: Opus Genetics (IRD) Non-Current Debt (2025 - 2026) | Business Quant
Creator: Business Quant

Opus Genetics (IRD) reported Non-Current Debt of $1.2 million for Q1 2026, up 6.11% on a QoQ basis from $1.1 million in Q4 2025.

Opus Genetics (IRD) has 2 years of Non-Current Debt data on file, last reported at $1.2 million in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, changed N/A from the prior year.
Non-Current Debt rose to $1.2 million in Q1 2026 per IRD's latest filing, from $1.1 million in the prior quarter.
Across five years, Non-Current Debt topped out at $1.2 million in Q1 2026 and bottomed at $1.0 million in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	319.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	105.94 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	1.99 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Opus Genetics	357.99 Mn	298.03 Mn	-	1.20 Mn

Download Data 🔒